Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2022, 4(1); doi: 10.25236/IJFM.2022.040103.

The Effects of Sacubitril / Valsartan on Major Adverse Cardiac Events to the Patients of Acute Myocardial Infarction: A Meta-analysis


Mei Liu1, Ying Yang1, Shujuan Li2, Yanan He1

Corresponding Author:
Ying Yang

1The First Affiliated Hospital of Dali University, Dali 671000, Yunnan, China

2Yunnan Institute of Endemic Disease Control, Dali 671000, Yunnan, China


Sacubitril / valsartan is widely used in the patients of heart failure (HF) as an angiotensin receptor-neprilysin inhibitor (ARNI). However, the effects in patients of acute myocardial infarction (AMI) remain unclear. Therefore, in the patients of AMI,we performed this meta-analysis to explore the effects of ARNI on major adverse cardiac events(MACEs). We searched Cochrane Library, Pub-Med, Web of Science, Embase, China National Knowledge Infrastructure, WanFang, and VIP for randomized controlled trials (RCTs) published up to January 2021, with no language restrictions, compared angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) with ARNI to analyze their effects on MACEs in patients with AMI. All studies met the inclusion and exclusion criteria. PROSPERO registration: CRD42021256018. Our primary outcomes were MACEs, including all-cause mortality, nonfatal myocardial infarction, hospitalization for HF, malignant car-diac event or cardiac death, stroke,re-admission for cardiovascular disease, angina pectoris, malig-nant arrhythmia, and coronary artery reconstruction. Secondary outcomes included acute or sub-acute thrombosis, bleeding again, and nonfatal cardiogenic shock. Eleven RCTs (1,125 patients) were recruited. Compared with ACEI / ARBs, sacubitril / valsartan decreased the hospitalization rates for HF (odds ratio(OR), 0.44; 95% confidence interval (CI): 0.33-0.59) and re-admission for cardiovascular diseases (OR, 0.41; 95% CI: 0.18-0.94) in patients with AMI. However, no obvious benefits were found on other MACEs. In the patients of AMI, sacubitril / valsartan decreased the hos-pitalization rate for HF and re-admission for cardiovascular disease compared with ACEI/ARBs, with no obvious effects on other MACEs.


Sacubitril / Valsartan. Major Adverse Cardiac Events (MACEs). Acute Myocardial Infarc-tion (AMI). Meta-analysis

Cite This Paper

Mei Liu, Ying Yang, Shujuan Li, Yanan He. The Effects of Sacubitril / Valsartan on Major Adverse Cardiac Events to the Patients of Acute Myocardial Infarction: A Meta-analysis. International Journal of Frontiers in Medicine (2022), Vol. 4, Issue 1: 11-18. https://doi.org/10.25236/IJFM.2022.040103.


[1] Poudel I, Tejpal C, Hamza Rashid NJ. Major adverse cardiovascular events: an inevitable out-come of ST-elevation myocardial infarction? A literature review. Cureus. 2019; 11(7).

[2] Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary inter-vention. Journal of the American College of Cardiology. 2008; 51(7):701-7.

[3] White HD, Chew DP. Acute myocardial infarction. The Lancet. 2008;372(9638):570-84.

[4] Yandrapalli S, Khan MH, Rochlani Y, Aronow WS. Sacubitril / valsartan in cardiovascular dis-ease: evidence to date and place in therapy. Therapeutic advances in cardiovascular disease. 2018; 12(8):217-31.

[5] Lefer DJ, Sharp TE. Angiotensin receptor-Neprilysin inhibitors emerge as potential treatment for acute myocardial infarction. American College of Cardiology Foundation Washington, DC; 2018.

[6] Yandrapalli S, Andries G, Biswas M, Khera S. Profile of sacubitril / valsartan in the treatment of heart failure: patient selection and perspectives. Vascular health and risk management. 2017; 13:369.

[7] Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril / valsartan. Heart. 2016; 102(17):1342-7.

[8] Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial In-farction (PARADISE-MI): Design and Baseline Characteristics. European journal of heart failure. 2021.

[9] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic re-views. 2015; 4(1):1-9.

[10] Rezq A, Saad M, El Nozahi M. Comparison of the Efficacy and Safety of Sacubitril / Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction. The American journal of cardiology. 2021; 143:7-13.

[11] Cai J. Effects of Sacubitril / Valsartan on ventricular remodeling and cardiac function in pa-tients undergoing emergency PCI after acute myocardial infarction. China Academic Journal Elec-tronic Publishing House: HeBei Medical University; 2020 (in Chinese).

[12] Chen CW, Qian WH, Ding H, Zhou H, Wang WH, University XM, et al. Effect of Shakuba Tri-valsartan on the Short-term Prognosis of Patients with Acute Anterior Wall Myocardial Infarction Complicated with Cardiac Insufficiency after Emergency PCI. (in Chinese).

[13] Fang LJCH-xCQ-yZWHJ-rFJ-jJ. Effect of sakubatrovalsartan on cardiac function after emer-gency percutaneous coronary intervention in patients with acute myocardial infarction. Chinese Journal of Clinical Research. 2020; 33(9): 1200-3 (in Chinese).

[14] Guang-hao ZR-yQZ-yG. Application of shakuba trvalsartan in the primary prevention of patients with acute myocardial infarction. South China Journal of Cardiovascular Diseases. 2021:in Chinese.

[15] Jiang D. Effect of Sacubitril Valsartan on cardiac function and cardiac load in patients with heart failure after acute myocardial infarction HeBei Medical University; 2020.

[16] Wang H, Fu X. Effects of sacubitril / valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coronary Ar-tery Disease. 2020; Publish Ahead of Print: in Chinese.

[17] WanG Hai-yan Jw-x, TIAN Li, Fu xiang -hua. Effects of sacubitril / Valsartan on cardiac func-tion in patients with acute anterior wall ST-segment elevation myocardial infarction after PCI with reduced ejection fraction Journal of HeBei Medical University. 2020; 41(3):254-8 (in Chinese).

[18] Yang Dong QD, Lei Yang, Wanliang Wang. Observation of the therapeutic effect of sacubitril and valsartan on patients with acute ST-segment elevation myocardial infarction combined with heart failure after emergency percutaneous coronary intervention: Clin J Med Offic; 2020 (in Chi-nese).

[19] Yuehua Z. Effect of LCZ696 on cardiac function in patients with Acute myocardial infarction complicated with Heart farlure. China Academic Journal Electronic Publishing House; 2020 (in Chi-nese).

[20] Zhang L. Effects of sacubitril and valsartan on cardiac function and adverse reactions in elderly patients with acute myocardial infarction. Department of Cardiology, Cangzhou Hospital of Inte-grated Traditional Chinese and Western Medicine; 2020 (in Chinese).

[21] Buggey J, Mentz RJ, DeVore AD, Velazquez EJ. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. Journal of cardiac failure. 2015; 21(9):741-50.

[22] Torrado J, Cain C, Mauro AG, Romeo F, Ockaili R, Chau VQ, et al. Sacubitril / valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits. Journal of the American College of Cardiology. 2018; 72(19):2342-56.

[23] von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarc-tion by reducing cardiac fibrosis and hypertrophy. Circulation: Heart Failure. 2015; 8(1):71-8.